The global xatmep market size is anticipated to expand at a substantial CAGR during the forecast period, between 2021 and 2028. Xatmep is a metabolic inhibitor of folate analogs. Xatmep is a chemotherapy agent as well as an immune suppressant. Methotrexate is the generic name of Xatmep. It is approved for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (PJIA). In April 2017, Azurity Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) had approved Xatmep (methotrexate) Oral Solution, the first and only FDA-approved methotrexate oral solution.
Market Trends, Drivers, Restraints, and Opportunities:
- Increasing use of the oral solution in chemotherapy for pediatric patients has greatly aided in the development of novel drugs around the world, which is a driving the market.
- Growing worldwide population, and increasing demand for pharmaceutical manufacturing drugs, are expected to drive demand for Xatmep in the coming years.
- Rising cancer prevalence worldwide, as well as a rapidly increasing birth rate, are driving factors for the Xatmep market.
- Growing autoimmune diseases such as active polyarticular juvenile idiopathic arthritis drive the market.
- Rigorous FDA guidelines for new drug approval, particularly for children, and adverse effects such as mouth sores, diarrhea, nausea, vomiting, abdominal distress, fatigue after treatment hinder the global xatmep market.
- Increasing technological innovations in generic drug treatment, rising healthcare spending are creating lucrative opportunities for market growth during the forecast period.
Scope of the report:
The report on the xatmep market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Xatmep Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Dose Types (2mg/ml and 2.5mg/ml), Applications (Acute Lymphoblastic Leukemia, Active Polyarticular Juvenile Idiopathic Arthritis, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), End-users (Hospitals, Specialty Clinics, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Azurity Pharmaceuticals, Inc. and Silvergate Pharmaceuticals
|
Xatmep Market Segment Insights:
The 2.5mg/ml segment is projected to hold a significant market share
In terms of dose types, the xatmep market is bifurcated into 2mg/ml and 2.5mg/ml. The 2.5mg/ml segment held a significant share of the market in 2020. Xatmep is approved by FDA as a commercially 2.5mg/ml dose for cancer, and autoimmune diseases. Also, xatmep oral solution, 2.5 mg/mL, is a ready-to-use product, & allowing for greater accuracy and ease of dispensing at the pharmacy is projected to drive the segment.
The acute lymphoblastic leukemia segment held a substantial market share in 2020
Based on applications, the market is fragmented into acute lymphoblastic leukemia, active polyarticular juvenile idiopathic arthritis, and others. The acute lymphoblastic leukemia segment accounts for a significant share of the market, and is projected to expand at a rapid rate during the forecast period. Xatmep is a chemotherapy agent used in cancer treatment for pediatric patients, and continuous increase in R&D in innovative drug development.
The hospital pharmacy segment to grow rapidly during the forecast period
Based on distribution channels, the market is segregated into hospital pharmacy, retail pharmacy, mail-order service, and others. The hospital pharmacy segment is expected to hold a substantial share of the market during the forecast period, owing to the global pharmaceutical industry's increased investment in R&D, rising healthcare expenditure, and increasing hospitalization cases globally.
The hospitals segment to grow rapidly during the forecast period
Based on end-users, the market is segregated into hospitals, specialty clinics, and others. The hospitals segment is anticipated to hold a significant share of the market during the forecast period. Hospital segment is the market's leading service provider for cancer treatment, advanced medical facilities, growing R&D expenditure, and high patient traffic is expected to boost the segment.
North America dominates the global market
In terms of regions, the global xatmep market is split into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held a significant share of the market, due to rising prevalence of acute leukemia, and pharmaceutical companies focusing on developing novel formulations for the pediatric population. Europe held a substantial market share in the region, owing to a growing population, high healthcare spending, and improved cancer & related surgeries in the region. The market in Asia Pacific is expected to grow rapidly in the forecast periods, due to growing population, rising chronic disorders, rising government initiatives, and pharmaceutical companies to spread awareness and the presence of generic manufacture, these factors contribute to the region's market growth.
Segments
Segments Covered in the Report
By Dose Types
By Applications
- Acute Lymphoblastic Leukemia (ALL)
- Active Polyarticular Juvenile Idiopathic Arthritis (PJIA)
- Other
By Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Mail-order service
- Others
By End-users
- Hospitals
- Specialty Clinics
- Others
By Regions
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
Key Players
- Azurity Pharmaceuticals, Inc.
- Silvergate Pharmaceuticals
Competitive Landscape
Key players in the xatmep market include Azurity Pharmaceuticals, Inc. and Silvergate Pharmaceuticals. Global alliances and mergers and acquisitions among leading research institutes to accelerate drug discovery in the future, these companies focus on expanding their geographical presence.
Request For Customization
Enquiry Before Buying
Speak With Analyst
